SynthesisAsian Pacific journal of cancer prevention : APJCP2025
Effect of HER3 Overexpression on Survival Outcomes in Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinicopathological and Prognostic Significance of TROP2 and HER3 Expression in Early-Stage Cervical Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Roles of Her3 in carcinogenesis and advances in Her3-targeted cancer therapy.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) is a highly aggressive malignancy known for its late diagnosis and poor prognosis, making it one of the leading causes of cancer-related mortality worldwide. Identifying the molecular alterations involved in the prognosis of PC is essential. One such factor is HER3 overexpression, which can contribute to cancer cell survival, metastasis, and reduced overall survival (OS) in patients by activating cellular signaling pathways. This meta-analysis investigates the rate of HER3 overexpression in pancreatic cancer patients and examines how this overexpression affects their survival rates. MATERIALS AND
methodsA comprehensive search was conducted across PubMed, Embase, Web of Science, and Scopus databases up to August 2024. Studies evaluating the association between HER3 overexpression and PC were collected following specific inclusion and exclusion criteria. The rate ratio (RR) with 95% confidence intervals (CI) was calculated. Heterogeneity and publication bias were evaluated, and the extent of HER3 overexpression in patients with PC was analyzed. Also, the studies' quality was evaluated using the Newcastle-Ottawa Quality Assessment Scale. The research protocol has been registered on PROSPERO under the registration number CRD42024584939.
resultsFour studies involving 345 patients with PC were selected for analysis to assess the role of HER3 overexpression on OS. Seven studies involving 536 patients were also included to evaluate the rate of HER3 overexpression in PC patients. Findings indicate that 47.8% of PC patients showed overexpression of HER3 (CI 95%: 34.1-61.9). Additionally, HER3 overexpression was significantly linked to a poorer overall survival rate of patients with PC (OR: 0.605, 95% CI: 0.401-0.913, P= 0.017).
conclusionIn summary, our results reveal that a significant proportion of PC patients show overexpression of HER3, suggesting its potential role as a target for immunotherapy. The findings also highlight the promise of HER3 as a prognostic biomarker in PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.